
From: Mike Williams
To: 'Blaxill Mark'; Sallie Bernard
CC: tlredwood@mindspring.com
Sent: 2/24/2004 4:14:30 PM
Subject: RE: Validating the Geiers' VSD work

Thanks, Mark, very helpful.

-----Original Message-----

From: Blaxill Mark [mailto:Blaxill.Mark@BCG.com]
Sent: Tuesday, February 24, 2004 1:05 PM
To: Mike Williams; Sallie Bernard
Cc: tlredwood@mindspring.com
Subject: RE: Validating the Geiers' VSD work

Mike,

In the interest of full disclosure, I thought you might be interested to see my critique of the Geiers' latest work on VSD. I have not been a big fan of the Geiers. I worry they do not represent our side well. They often do sloppy work.

FWIW,
Mark

-----Original Message-----

From: Mike Williams [mailto:michael_williams@wdolaw.com]
Sent: Tuesday, February 24, 2004 3:29 PM
To: Sallie Bernard
Cc: blaxill.mark@bcg.com; tlredwood@mindspring.com
Subject: Validating the Geiers' VSD work

Sallie, I just had another conf call with our two Emory experts, and one project we are definitely going forward with is to seek access for them to the VSD data to check the Geiers' work on HMOB, and extend it to include diagnoses of autism and other outcomes of interest into the end of 2003, three more years of diagnosis time for the 1997-99 birth cohorts in their study. Dr. Harland Austin and his biostat assistant Cathy Lally are working on a revision of the attached proposed protocol, and we plan on submitting it formally to the CDC and the DOJ lawyers by the middle of March or so. I welcome any comments you all might have on it. <<Geier_analysisJan04.doc>> They have also written an analysis of the changes in the Verstraeten CDC Tm screening analysis, on which we are basing a motion to compel the CDC to give us the background materials for the study (all changes in the protocols, all status reports, all emails among the authors, to start with). I also attach Dr. Austin's latest version of that analysis and would appreciate your suggestions or comments. <<Contrast_Two_StudiesHAustinJan04.doc>>

* * CONFIDENTIALITY NOTICE * *

This e-mail message is intended for the sole use of the intended recipient and may contain information that is privileged, confidential and exempt from disclosure under law. Distribution or duplication of this e-mail by someone other than the intended recipient is strictly prohibited.

This e-mail message may contain confidential and/or privileged information. If you are not an addressee or otherwise authorized to receive this message, you should not use, copy, disclose or take any action based on this e-mail or any information contained in the message. If you have received this material in error, please advise the sender immediately by reply e-mail and delete this message.

Thank you.

PSC/WP-00026692